Advanced Filters
noise

leukemia Clinical Trials

A listing of leukemia medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 1,150 clinical trials
F Filippo Milano

Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies

This phase II trial studies how well a donor stem cell transplant, treosulfan, fludarabine, and total-body irradiation work in treating patients with blood cancers (hematological malignancies). Giving chemotherapy and total-body irradiation before a donor stem cell transplant helps stop the growth of cells in the bone marrow, including normal blood-forming …

6 years of age All Phase 2

Micro-transplantation in Elderly Patients With Acute Myeloid Leukemia

This study aims at evaluating the safety and the tolerance of the micro-transplantation in elderly patients with acute myeloid leukemia who are ineligible to conventional allogeneic transplantation.

60 - 75 years of age All Phase N/A

AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

The primary objective is to define the safety and tolerability of AB8939 in patients with AML by determining the dose-limiting toxicities, the maximum tolerated dose, and the recommended dose for dose expansion study.

18 years of age All Phase 1/2
S Sheng-Li Xue, M.D.

CD19 CAR-T Consolidation Therapy for Acute Lymphoblastic Leukemia

This is a single arm, open-label, single-center, phase I/II study to determine the safety and efficacy of CD19 CAR-T( ssCART-19) combined with feeding T cells (FTCs) as consolidation therapy in patients diagnosed with de novo Philadelphia chromosome positive CD19+ B-ALL. The study will contain the following sequential phases: screening, lymphocyte …

18 - 60 years of age All Phase 1/2
L Li Yu

CD7 CAR-T Cells in T-cell Lymphoma/Leukemia

T-cell lymphoma/leukemia is a group of highly lethal diseases with a high relapse rate and poor prognosis. CD7 was proved to be widely expressed in T-cell malignant, which makes it a promising therapeutic target. In this study we aim to test the safety and efficacy of CD7 CAR-T cells in …

18 - 75 years of age All Phase N/A
r riling chen, M.D

Treateament of Newly Diagnosed Acute Monocytic Leukemia in Children

This is a multicenter, single arm, prospective, intervention trial. Since cladribine can enhance the biological activity and self-protection of cytarabine, giving cladribine and cytarabine together may kill more cancer cells. 10 centers from South China Childhood Leukaemia Collaborative Group carry out the SCCLG-M5-2022 regimen including two courses of CLAG(cladribine, darubicin …

1 - 14 years of age All Phase 2/3
C Cindy Taylor

Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia

This study will evaluate fixed-duration therapy with pirtobrutinib and obinutuzumab given over 12 cycles (approximately 1 year) as first-line treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL or SLL).

18 years of age All Phase 2
S Suping ZHANG

Blinatumomab for Relapsed Acute B Lymphoblastic Leukemia After Transplantation

B-ALL patients received regular follow-up after allogeneic hematopoietic stem cell transplantation, and in case of recurrence, they were given Blinatumomab. Anti-treatment was followed by DLI, and the second course was performed 1-2 months after DLI. Patients with positive MRD were treated with Blinatumomab 28μg×5-15 days, followed by DLI treatment. (MNC …

- 65 years of age All Phase 4
A Abhishek Maiti, MD

CER-1236 in Patients With Acute Myeloid Leukemia (AML)

This is a first in human, multi center, open label, phase 1/1b study to evaluate the safety and preliminary efficacy of CER-1236 in patients with relapsed/refractory (R/R), measurable residual disease (MRD) positive acute myeloid leukemia (AML), or TP53mut disease.

18 - 85 years of age All Phase 1
J Jin Jie

Study of YK012 in B-cell Acute Lymphoblastic Leukemia

The purpose of this study is to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of YK012 administered as monotherapy in participants with B-cell acute lymphoblastic leukemia (B-ALL).

18 - 75 years of age All Phase 1/2

Simplify language using AI